Clinical Trials in Neurovirology: Successes, Challenges, and Pitfalls

No abstract is available for this paper.

• Publication year

  2016

• Venue

  Neurotherapeutics

• Publication date

  2016-05-18

• Fields of study

  Medicine

• Identifiers
  DOI 10.1007/s13311-016-0440-8PMID 27194073PMCID PMC4965408
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Evaluating interventions for Ebola: The need for randomized trials

  2016cited by this paper
• Conducting clinical trials in outbreak settings: Points to consider

  2016cited by this paper
• Long-Term Mortality in HIV-Infected Individuals 50 Years or Older: A Nationwide, Population-Based Cohort Study

  2016cited by this paper
• Clinical validation trial of a diagnostic for Ebola Zaire antigen detection: Design rationale and challenges to implementation

  2016cited by this paper
• Maraviroc-intensified combined antiretroviral therapy improves cognition in virally suppressed HIV-associated neurocognitive disorder

  2016cited by this paper
• Statistical considerations for a trial of Ebola virus disease therapeutics

  2016cited by this paper
• A response adaptive randomization platform trial for efficient evaluation of Ebola virus treatments: A model for pandemic response

  2016cited by this paper
• Neurocognitive change in the era of HIV combination antiretroviral therapy: the longitudinal CHARTER study.

  2015cited by this paper
• Exploring the ethical and regulatory issues in pragmatic clinical trials

  2015cited by this paper
• Could antiretroviral neurotoxicity play a role in the pathogenesis of cognitive impairment in treated HIV disease?.

  2015cited by this paper
• Randomized trial of central nervous system-targeted antiretrovirals for HIV-associated neurocognitive disorder.

  2014cited by this paper
• Treating progressive multifocal leukoencephalopathy with interleukin 7 and vaccination with JC virus capsid protein VP1.

  2014cited by this paper
• Cerebral metabolite changes prior to and after antiretroviral therapy in primary HIV infection

  2014cited by this paper
• Treatment of progressive multifocal leukoencephalopathy with interleukin 7.

  2014cited by this paper
• Low levels of HIV-1 RNA detected in the cerebrospinal fluid after up to 10 years of suppressive therapy are associated with local immune activation

  2014cited by this paper
• Single-patient (n-of-1) trials: a pragmatic clinical decision methodology for patient-centered comparative effectiveness research.

  2013cited by this paper
• Recent issues in herpes simplex encephalitis

  2013cited by this paper
• Cerebrospinal fluid neopterin decay characteristics after initiation of antiretroviral therapy

  2013cited by this paper
• HIV DNA Reservoir Increases Risk for Cognitive Disorders in cART-Naïve Patients

  2013cited by this paper
• Rivastigmine for HIV-associated neurocognitive disorders

  2013cited by this paper
• Closing the Gap: Increases in Life Expectancy among Treated HIV-Positive Individuals in the United States and Canada

  2013cited by this paper
• A study of mefloquine treatment for progressive multifocal leukoencephalopathy: results and exploration of predictors of PML outcomes

  2013cited by this paper
• Elevated sCD163 in plasma but not cerebrospinal fluid is a marker of neurocognitive impairment in HIV infection

  2013cited by this paper
• Use of central institutional review boards for multicenter clinical trials in the United States: A review of the literature

  2013cited by this paper
• Sample size formulae for the Bayesian continual reassessment method

  2013cited by this paper
• Cerebrospinal fluid and neuroimaging biomarker abnormalities suggest early neurological injury in a subset of individuals during primary HIV infection.

  2013cited by this paper
• PML diagnostic criteria

  2013cited by this paper
• Adaptive trial designs: a review of barriers and opportunities

  2012cited by this paper
• EFNS‐ENS guidelines for the use of PCR technology for the diagnosis of infections of the nervous system

  2012cited by this paper
• Management of suspected viral encephalitis in adults--Association of British Neurologists and British Infection Association National Guidelines.

  2012cited by this paper
• Cerebrospinal fluid HIV escape associated with progressive neurologic dysfunction in patients on antiretroviral therapy with well controlled plasma viral load

  2012cited by this paper
• Progressive multifocal leukoencephalopathy in transplant recipients

  2011cited by this paper
• Improved Survival of HIV-1-Infected Patients with Progressive Multifocal Leukoencephalopathy Receiving Early 5-Drug Combination Antiretroviral Therapy

  2011cited by this paper
• Treatment Intensification Has no Effect on the HIV-1 Central Nervous System Infection in Patients on Suppressive Antiretroviral Therapy

  2010cited by this paper
• Impact of combination antiretroviral therapy on cerebrospinal fluid HIV RNA and neurocognitive performance

  2009cited by this paper
• Cidofovir in addition to antiretroviral treatment is not effective for AIDS-associated progressive multifocal leukoencephalopathy: a multicohort analysis

  2008cited by this paper
• Validation of the CNS Penetration-Effectiveness rank for quantifying antiretroviral penetration into the central nervous system.

  2008cited by this paper
• Factors in AIDS Dementia Complex Trial Design: Results and Lessons from the Abacavir Trial

  2007cited by this paper
• Longitudinally preserved psychomotor performance in long-term asymptomatic HIV-infected individuals

  2007cited by this paper
• Evaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathy.

  2006cited by this paper
• Caution regarding the use of pilot studies to guide power calculations for study proposals.

  2006cited by this paper
• Progressive multifocal leukoencephalopathy complicating treatment with natalizumab and interferon beta-1a for multiple sclerosis.

  2005cited by this paper
• Impact of Efavirenz on Neuropsychological Performance and Symptoms in HIV-Infected Individuals

  2005cited by this paper
• Progressive multifocal leukoencephalopathy in a patient treated with natalizumab.

  2005cited by this paper
• Progressive multifocal leukoencephalopathy, natalizumab, and multiple sclerosis.

  2005cited by this paper
• Progressive multifocal leukoencephalopathy, natalizumab, and multiple sclerosis.

  2005cited by this paper
• Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn's disease.

  2005cited by this paper
• Progressive multifocal leukoencephalopathy in transplant recipients

  2004cited by this paper
• What makes clinical research in developing countries ethical? The benchmarks of ethical research.

  2004cited by this paper
• Topotecan in the treatment of acquired immunodeficiency syndrome-related progressive multifocal leukoencephalopathy

  2003cited by this paper
• Changes in CSF and plasma HIV-1 RNA and cognition after starting potent antiretroviral therapy

  2003cited by this paper
• Viral encephalitis: familiar infections and emerging pathogens.

  2002cited by this paper
• HIV-1 reverse transcriptase sequence in plasma and cerebrospinal fluid of patients with AIDS dementia complex treated with Abacavir

  2001cited by this paper
• Small Clinical Trials: Issues and Challenges

  2001cited by this paper
• Randomized trial of the platelet-activating factor antagonist lexipafant in HIV–associated cognitive impairment

  1999cited by this paper
• Relation of JC virus DNA in the cerebrospinal fluid to survival in acquired immunodeficiency syndrome patients with biopsy‐proven progressive multifocal leukoencephalopathy

  1999cited by this paper
• Brief Communications Expedited Publication HAART improves prognosis in HIV-associated progressive multifocal leukoencephalopathy

  1999cited by this paper
• Neurological outcomes in late HIV infection: adverse impact of neurological impairment on survival and protective effect of antiviral therapy. AIDS Clinical Trial Group and Neurological AIDS Research Consortium study team.

  1999cited by this paper
• A randomized, double-blind, placebo-controlled trial of deprenyl and thioctic acid in human immunodeficiency virus-associated cognitive impairment

  1998cited by this paper
• A phase I/II trial of nimodipine for HIV-related neurologic complications

  1998cited by this paper
• Failure of cytarabine in progressive multifocal leukoencephalopathy associated with human immunodeficiency virus infection. AIDS Clinical Trials Group 243 Team.

  1998cited by this paper
• A randomized, double-blind, placebo-controlled trial of deprenyl and thioctic acid in human immunodeficiency virus-associated cognitive impairment. Dana Consortium on the Therapy of HIV Dementia and Related Cognitive Disorders.

  1998cited by this paper
• Randomized double-blind placebo-controlled trial of peptide T for HIV-associated cognitive impairment.

  1998cited by this paper
• Progressive multifocal leukoencephalopathy in patients with HIV infection.

  1998cited by this paper
• Safety and tolerability of the antioxidant OPC-14117 in HIV-associated cognitive impairment. The Dana Consortium on the Therapy of HIV Dementia and Related Cognitive Disorders.

  1997cited by this paper
• Stable neurological function in subjects treated with 2'3'-dideoxyinosine.

  1997cited by this paper
• Relationship between human immunodeficiency virus—associated dementia and viral load in cerebrospinal fluid and brain

  1997cited by this paper
• Cerebrospinal fluid human immunodeficiency virus type 1 RNA levels are elevated in neurocognitively impaired individuals with acquired immunodeficiency syndrome

  1997cited by this paper
• Diagnosis of herpes simplex encephalitis: application of polymerase chain reaction to cerebrospinal fluid from brain-biopsied patients and correlation with disease. National Institute of Allergy and Infectious Diseases Collaborative Antiviral Study Group.

  1995cited by this paper
• Zidovudine treatment of the AIDS dementia complex: Results of a placebo‐controlled trial

  1993cited by this paper
• Rapid diagnosis of herpes simplex encephalitis by nested polymerase chain reaction assay of cerebrospinal fluid.

  1991cited by this paper
• Design considerations for AIDS trials.

  1990cited by this paper
• Diseases that mimic herpes simplex encephalitis. Diagnosis, presentation, and outcome. NIAD Collaborative Antiviral Study Group.

  1989cited by this paper
• Progressive multifocal leukoencephalopathy (PML) in AIDS.

  1988cited by this paper
• Neuropsychological outcome of zidovudine (AZT) treatment of patients with AIDS and AIDS-related complex.

  1988cited by this paper
• The AIDS dementia complex.

  1988cited by this paper
• Vidarabine versus acyclovir therapy in herpes simplex encephalitis.

  1986cited by this paper
• The AIDS dementia complex: II. Neuropathology

  1986cited by this paper
• The AIDS dementia complex: I. Clinical features

  1986cited by this paper
• Acyclovir versus vidarabine in herpes simplex encephalitis. Randomised multicentre study in consecutive Swedish patients.

  1984cited by this paper
• Acyclovir versus vidarabine in herpes simplex encephalitis. Randomised multicentre study in consecutive Swedish patients.

  1984cited by this paper
• Neurological complications of acquired immune deficiency syndrome: Analysis of 50 patients

  1983cited by this paper
• Adenine arabinoside therapy of biopsy-proved herpes simplex encephalitis.

  1977cited by this paper
• Adenine arabinoside therapy of biopsy-proved herpes simplex encephalitis. National Institute of Allergy and Infectious Diseases collaborative antiviral study.

  1977cited by this paper
• The combination of randomized and historical controls in clinical trials.

  1976cited by this paper
• Failure of high dose 5-iodo-2'-deoxyuridine in the therapy of herpes simplex virus encephalitis. Evidence of unacceptable toxicity.

  1975cited by this paper
• Non-randomized controls in cancer clinical trials.

  1974cited by this paper
• Identification and Characterization of Mefloquine Efficacy against JC Virus In Vitro (cid:1) †

  year unknowncited by this paper

• Principles of Neurochemistry: Fundamentals and Applications

  2020cites this paper
• Neuropharmacology: Looking Forward to the Future

  2020cites this paper
• Insights into the pathogenesis of herpes simplex encephalitis from mouse models

  2018cites this paper
• Drug‐induced progressive multifocal leukoencephalopathy in multiple sclerosis: European regulators' perspective

  2017cites this paper